Autologous hematopoietic progenitor cell mobilization and collection in adult patients presenting with multiple myeloma and lymphoma: A position-statement from the Turkish Society of Apheresis (TSA)

Basit Öğe Kaydı
dc.contributor.authorTekgunduz, Emre
dc.contributor.authorArat, Mutlu
dc.contributor.authorGoker, Hakan
dc.contributor.authorOzdogu, Hakan
dc.contributor.authorKaynar, Leylagul
dc.contributor.authorCagirgan, Seckin
dc.contributor.authorErkurt, Mehmet Ali
dc.contributor.authorVural, Filiz
dc.contributor.authorKiki, Ilhami
dc.contributor.authorAltuntas, Fevzi
dc.contributor.authorDemirkan, Fatih
dc.date.accessioned2019-10-27T10:47:23Z
dc.date.available2019-10-27T10:47:23Z
dc.date.issued2017
dc.departmentEge Üniversitesien_US
dc.description.abstractAutologous hematopoietic cell transplantation (AHCT) is a routinely used procedure in the treatment of adult patients presenting with multiple myeloma (MM), Hodgkin lymphoma (HL) and various subtypes of non-Hodgkin lymphoma (NHL) in upfront and relapsed/refractory settings. Successful hematopoietic progenitor cell mobilization (HPCM) and collection are the rate limiting first steps for application of AHCT. In 2015, alinost 1700 AHCT procedures have been performed for MM, HL and NHL in Turkey. Although there are recently published consensus guidelines addressing critical issues regarding autologous HPCM, there is a tremendous heterogeneity in terms of mobilization strategies of transplant centers across the world. In order to pave the way to a more standardized HPCM approach in Turkey, Turkish Society of Apheresis (TSA) assembled a working group consisting of experts in the field. Here we report the position statement of TSA regarding autologous HPCM mobilization strategies in adult patients presenting with MM and lymphoma. (C) 2017 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.transci.2017.11.025en_US
dc.identifier.endpage849en_US
dc.identifier.issn1473-0502
dc.identifier.issue6en_US
dc.identifier.pmid29153306en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage845en_US
dc.identifier.urihttps://doi.org/10.1016/j.transci.2017.11.025
dc.identifier.urihttps://hdl.handle.net/11454/31414
dc.identifier.volume56en_US
dc.identifier.wosWOS:000423246100017en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofTransfusion and Apheresis Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAutologous hematopoietic cellen_US
dc.subjecttransplantationen_US
dc.subjectLymphomaen_US
dc.subjectMyelomaen_US
dc.subjectMobilizationen_US
dc.titleAutologous hematopoietic progenitor cell mobilization and collection in adult patients presenting with multiple myeloma and lymphoma: A position-statement from the Turkish Society of Apheresis (TSA)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu